期刊文献+

齐拉西酮治疗老年精神分裂症的临床研究 预览

Study of Ziprasidone in treatment of elderly schizophrenia
在线阅读 下载PDF
收藏 分享 导出
摘要 目的比较齐拉西酮和奋乃静治疗老年精神分裂症的疗效和安全性。方法将72例老年精神分裂症患者随机分为2组,分别给予齐拉西酮和奋乃静治疗8周。采用阳性与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定不良反应。结果治疗8周后,齐拉西酮组与奋乃静组疗效比较差异无统计学意义(P〉0.05),齐拉西酮组不良反应程度、发生率均少而轻。结论齐拉西酮治疗老年精神分裂症患者疗效好,不良反应相对较小。 Objective To compare clinical efficacy and safety between ziprasidone and perphenazine in the treatment of eld- erly schizophrenia. Methods 72 cases of elderly patients with schizophrenia were randomly divided into ziprasidone group and per- phenazine group for 8 weeks. Positive and Negative Syndrome Scale (PANSS) was used to assess the efficacy, side effects scale (TESS) was used to assess adverse reactions. Results After 8 weeks, effective rate of ziprasidone group was 69.44%, with a total effective rate was 88.89% ;perphenazine group were 63.89% and 86.11%, respectively, no statistical difference in therapeutic effect (P 〉 0.05). However, compared to perphenazine group, adverse reactions of ziprasidone group were much smaller and lighter. Con- clusion Ziprasidone in treatment of elderly schizophrenia is of good efficacy and relatively small adverse reactions.
作者 黄峰 HUANG Feng ( Social Welfare Hospital of Guilin,Guilin 541001, China)
出处 《内科》 2010年第1期 5-6,共2页 Internal Medicine of China
关键词 老年精神分裂症 齐拉西酮 奋乃静 Elderly Schizophrenia Ziprasidone Perphenazine
  • 相关文献

参考文献8

二级参考文献18

  • 1周远大,吴妍,何海霞.齐拉西酮片剂的人体药动学[J].中国新药与临床杂志,2006,25(2):95-97. 被引量:6
  • 2李华芳,谢世平,李鸣,张明廉,李静,苏炳华,顾牛范.齐拉西酮治疗精神分裂症的随机、双盲、双模拟、多中心研究[J].中国新药与临床杂志,2006,25(10):747-752. 被引量:64
  • 3李乐华,赵靖平,房茂胜,许秀峰,蒙华庆,宁洁.齐拉西酮与氟哌啶醇治疗精神分裂症随机双盲双模拟多中心对照研究[J].中国新药与临床杂志,2007,26(5):335-338. 被引量:35
  • 4MICELI JJ, WILNER KD, HANSEN RA, et al. Single and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers [J]. Br J Clin Pharmacol, 2000, 49 Suppl 1: 5S-13S. 被引量:1
  • 5MICELI JJ, ANZIANO RJ, ROBARGE L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of zipra- sidone in healthy volunteers[J]. Br J Clin Pharmacol, 2000, 49 Suppl 1 : 65S-70S. 被引量:1
  • 6SIMPSON GM, GLICK ID, WEIDEN PJ, et al. Randomized, controlled, double-blind muhicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder[J]. Am J Psychiatry, 2004, 161(10): 1837-1847. 被引量:1
  • 7STAHI SM, SHAYEGAN DK. The psychopharmacology of ziprasidone: receptor-binding propreties and real-world psychiatric practice[J]. J Clin Psychiatry, 2003,64 Suppl 19 : 6-12. 被引量:1
  • 8CALEY CF, COOPER CK. Ziprasidone: the fifth atypical antipsychotie[J]. Ann Pharmaeother. 2002, 36(5 ) : 839-851. 被引量:1
  • 9KANE JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials[J]. J Clin Psychiatry, 2003, 64 Suppl 19:19-25. 被引量:1
  • 10HARVEY PD, SIU CO, ROMANO S. Randomized, controlled,double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder[J]. Psychopharmacology, 2004, 172(3) :324-332. 被引量:1

共引文献1976

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏